妊娠期接种第三剂SARS-CoV-2疫苗(加强针)的安全性
本回顾性队列研究纳入2021年7月至10月在一家大型三级医疗中心分娩的6507名妇女,比较妊娠期接种第三剂SARS-CoV-2疫苗者与未接种者及仅接种两剂者的产科结局。结果显示三剂接种组与未接种组或两剂组在早产和小于胎龄儿方面无差异,但三剂组产后出血率较高。
要点
- 妊娠期接种第三剂SARS-CoV-2疫苗与未接种或仅接种两剂相比,早产和小于胎龄儿发生率无差异。
- 三剂接种组产后出血率高于未接种组(9.5% vs 3.21%,P<.001)和两剂组(9.5% vs 3.5%,P<.001)。
- 三剂组妊娠期糖尿病率高于未接种组(12.2% vs 8.3%,P=.02),妊娠期高血压疾病率低于未接种组(0% vs 1.4%,P=.041)。
核心结论
- 妊娠期接种SARS-CoV-2疫苗加强针与未接种或仅接种两剂者相比,未发现不良产科结局相关,但观察到产后出血率较高。
- 需要更大规模的研究来确认这些发现。
研究设计与样本
- 回顾性队列研究,纳入2021年7月至10月在一家大型三级医疗中心分娩的妇女。
- 共6507名妇女符合纳入标准:294名接种三剂疫苗,2845名仅接种两剂,3368名未接种。
- 主要结局为早产和小于胎龄儿的发生率,次要结局为其他母儿并发症。
- 采用多变量逻辑回归模型校正潜在混杂因素。
主要发现
- 三剂接种组、两剂接种组和未接种组在早产和小于胎龄儿发生率方面无差异。
- 三剂组产后出血率高于未接种组(9.5% vs 3.21%,P<.001)。
- 三剂组妊娠期糖尿病率高于未接种组(12.2% vs 8.3%,P=.02)。
- 三剂组妊娠期高血压疾病率低于未接种组(0% vs 1.4%,P=.041)。
- 与两剂组相比,三剂组产后出血率更高(9.5% vs 3.5%,P<.001),低脐动脉pH发生率更低(0.7% vs 6.1%,P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更大规模的研究来确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19 during pregnancy is associated with adverse outcomes for both the mother and fetus. SARS-CoV-2 vaccination has significantly reduced the risk for symptomatic disease. Several studies have reported on the safety of SARS-CoV-2 vaccination during pregnancy, with no adverse effects on the obstetrical outcomes. However, data regarding the obstetrical outcomes following a booster dose of the SARS CoV-2 vaccination during pregnancy have not yet to be published. OBJECTIVE: This study aimed to examine the association between the booster dose of the SARS CoV-2 vaccination during pregnancy and obstetrical outcomes. STUDY DESIGN: This was a retrospective cohort study of women who delivered between July and October 2021 at a large tertiary medical center. We compared women who received the booster vaccination dose during pregnancy with women who were not vaccinated and with those who only received 2 vaccination doses. Primary outcomes were the incidence of preterm labor and of small for gestational age neonates. Secondary outcomes were other maternal and neonatal complications. A secondary analysis investigating the association between the time from vaccination to delivery and the outcomes was also performed. Multivariable logistic regression models were used to adjust for potential confounders. RESULTS: There were 6507 women who met the inclusion criteria: 294 women received 3 doses of the vaccination, 2845 women received only 2 doses, and 3368 were unvaccinated. Patients receiving 3 doses of the vaccine were older and more likely to smoke than unvaccinated patients. No differences were noted among the triple-vaccinated, twice-vaccinated, and unvaccinated groups with regards to preterm birth and the incidence of small for gestational age neonates. Regarding the secondary outcomes, women in the triple-vaccinated group had higher rates of postpartum hemorrhage (9.5% vs 3.21%; P<.001) and gestational diabetes mellitus (12.2% vs 8.3%; P=.02) and were less likely to have hypertensive disorders of pregnancy (0% vs 1.4%; P=.041) than the unvaccinated group. Compared with the twice-vaccinated patients, patients with 3 doses of the vaccine were more likely to experience postpartum hemorrhage (9.5% vs 3.5%; P<.001) and were less likely to have a low umbilical artery pH (0.7% vs 6.1%; P<.001). In the sensitivity analysis comparing patients who delivered within 2 weeks of the third vaccination dose (n=53) with those who delivered at least 6 weeks after vaccination (n=96), there were no differences in the rates of small for gestational age neonates, preterm birth, postpartum hemorrhage, or cesarean delivery. CONCLUSION: Receiving the booster dose of the SARS-CoV-2 vaccination during pregnancy was not associated with adverse obstetrical outcomes when compared with unvaccinated or twice-vaccinated women. However, higher rates of postpartum hemorrhage were observed. Further studies on a larger scale are needed to confirm these findings.
引用
- Dick A, Rosenbloom JI, Karavani G, et al. Safety of third SARS-CoV-2 vaccine (booster dose) during pregnancy. Am J Obstet Gynecol MFM. 2022. PMID: 35398583. doi:10.1016/j.ajogmf.2022.100637
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。